139 related articles for article (PubMed ID: 38416116)
1. Structure-Based Design of Novel G-Protein-Coupled Receptor TAAR1 Agonists as Potential Antipsychotic Drug Candidates.
Zhou Z; Zhang W; Zhao F; Sun Y; Wang N; Cheng J; Zhan P; Yang F; Sun JP; Liu X; Kang D
J Med Chem; 2024 Mar; 67(5):4234-4249. PubMed ID: 38416116
[TBL] [Abstract][Full Text] [Related]
2. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.
Revel FG; Moreau JL; Pouzet B; Mory R; Bradaia A; Buchy D; Metzler V; Chaboz S; Groebke Zbinden K; Galley G; Norcross RD; Tuerck D; Bruns A; Morairty SR; Kilduff TS; Wallace TL; Risterucci C; Wettstein JG; Hoener MC
Mol Psychiatry; 2013 May; 18(5):543-56. PubMed ID: 22641180
[TBL] [Abstract][Full Text] [Related]
3. Structural and signaling mechanisms of TAAR1 enabled preferential agonist design.
Shang P; Rong N; Jiang JJ; Cheng J; Zhang MH; Kang D; Qi L; Guo L; Yang GM; Liu Q; Zhou Z; Li XB; Zhu KK; Meng QB; Han X; Yan W; Kong Y; Yang L; Wang X; Lei D; Feng X; Liu X; Yu X; Wang Y; Li Q; Shao ZH; Yang F; Sun JP
Cell; 2023 Nov; 186(24):5347-5362.e24. PubMed ID: 37963465
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.
Dedic N; Dworak H; Zeni C; Rutigliano G; Howes OD
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947997
[TBL] [Abstract][Full Text] [Related]
5. Binding of SEP-363856 within TAAR1 and the 5HT
Nair PC; Miners JO; McKinnon RA; Langmead CJ; Gregory KJ; Copolov D; Chan SKW; Bastiampillai T
Mol Psychiatry; 2022 Jan; 27(1):88-94. PubMed ID: 34376825
[TBL] [Abstract][Full Text] [Related]
6. TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT
Saarinen M; Mantas I; Flais I; Ågren R; Sahlholm K; Millan MJ; Svenningsson P
Neuropsychopharmacology; 2022 Dec; 47(13):2319-2329. PubMed ID: 36100653
[TBL] [Abstract][Full Text] [Related]
7. A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia.
Kane JM
J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5 Suppl 1):S1-S13. PubMed ID: 36099402
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of the Trace Amine Receptor, TAAR-1, in the Prefrontal Cortex of Individuals Affected by Schizophrenia.
Imbriglio T; Alborghetti M; Bruno V; Battaglia G; Nicoletti F; Cannella M
Schizophr Bull; 2024 Mar; 50(2):374-381. PubMed ID: 37897399
[TBL] [Abstract][Full Text] [Related]
9. Biological evaluation and
Wang Y; Liu Z; Lu J; Wang W; Wang L; Yang Y; Wang H; Ye L; Zhang J; Tian J
Front Pharmacol; 2023; 14():1161964. PubMed ID: 37153799
[No Abstract] [Full Text] [Related]
10. TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
Milanović S; Dedic N; Lew R; Burton D; Koblan KS; Camilleri M; Hopkins SC
Diabetes Obes Metab; 2024 Jun; 26(6):2466-2475. PubMed ID: 38533552
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics.
Ågren R; Betari N; Saarinen M; Zeberg H; Svenningsson P; Sahlholm K
Int J Neuropsychopharmacol; 2023 Sep; 26(9):599-606. PubMed ID: 37549917
[TBL] [Abstract][Full Text] [Related]
12. SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D
Dedic N; Jones PG; Hopkins SC; Lew R; Shao L; Campbell JE; Spear KL; Large TH; Campbell UC; Hanania T; Leahy E; Koblan KS
J Pharmacol Exp Ther; 2019 Oct; 371(1):1-14. PubMed ID: 31371483
[TBL] [Abstract][Full Text] [Related]
13. TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding.
Dedic N; Wang L; Hajos-Korcsok E; Hecksher-Sørensen J; Roostalu U; Vickers SP; Wu S; Anacker C; Synan C; Jones PG; Milanovic S; Hopkins SC; Bristow LJ; Koblan KS
Mol Metab; 2024 Feb; 80():101883. PubMed ID: 38237896
[TBL] [Abstract][Full Text] [Related]
14. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders.
Halff EF; Rutigliano G; Garcia-Hidalgo A; Howes OD
Trends Neurosci; 2023 Jan; 46(1):60-74. PubMed ID: 36369028
[TBL] [Abstract][Full Text] [Related]
15. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics.
Revel FG; Moreau JL; Gainetdinov RR; Ferragud A; Velázquez-Sánchez C; Sotnikova TD; Morairty SR; Harmeier A; Groebke Zbinden K; Norcross RD; Bradaia A; Kilduff TS; Biemans B; Pouzet B; Caron MG; Canales JJ; Wallace TL; Wettstein JG; Hoener MC
Biol Psychiatry; 2012 Dec; 72(11):934-42. PubMed ID: 22705041
[TBL] [Abstract][Full Text] [Related]
16. Selective TAAR1 agonists induce conditioned taste aversion.
Liu J; Wu R; Johnson B; Zhang Y; Zhu Q; Li JX
Psychopharmacology (Berl); 2022 Oct; 239(10):3345-3353. PubMed ID: 36056214
[TBL] [Abstract][Full Text] [Related]
17. Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia.
Højlund M; Correll CU
Expert Opin Investig Drugs; 2022 Dec; 31(12):1279-1290. PubMed ID: 36533396
[TBL] [Abstract][Full Text] [Related]
18. Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers.
Harmeier A; Obermueller S; Meyer CA; Revel FG; Buchy D; Chaboz S; Dernick G; Wettstein JG; Iglesias A; Rolink A; Bettler B; Hoener MC
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2049-61. PubMed ID: 26372541
[TBL] [Abstract][Full Text] [Related]
19. FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia.
Nishiyama K; Suzuki H; Harasawa T; Suzuki N; Kurimoto E; Kawai T; Maruyama M; Komatsu H; Sakuma K; Shimizu Y; Shimojo M
J Pharmacol Exp Ther; 2017 Nov; 363(2):253-264. PubMed ID: 28851764
[TBL] [Abstract][Full Text] [Related]
20. Ligand recognition and G-protein coupling of trace amine receptor TAAR1.
Xu Z; Guo L; Yu J; Shen S; Wu C; Zhang W; Zhao C; Deng Y; Tian X; Feng Y; Hou H; Su L; Wang H; Guo S; Wang H; Wang K; Chen P; Zhao J; Zhang X; Yong X; Cheng L; Liu L; Yang S; Yang F; Wang X; Yu X; Xu Y; Sun JP; Yan W; Shao Z
Nature; 2023 Dec; 624(7992):672-681. PubMed ID: 37935376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
